News Provided By: H&I Global Research Co.,Ltd

South Korea Prefilled Syringes Market

The South Korea prefilled syringes market is expected to grow at a CAGR of 4.32% from 2024 to 2032, driven by rising chronic diseases, stricter regulation, etc.TOKYO, JAPAN, April 1, 2025 /EINPresswire.com/ — South Korea, known for its advanced healthcare infrastructure and rapidly expanding biopharmaceutical industry, is witnessing rising adoption of prefilled syringes driven by multiple factors such as the growing burden of chronic diseases, an aging population, and the increasing preference for safe, precise, and patient-friendly drug delivery systems. Prefilled syringes, which offer premeasured doses of medication in sterile, ready-to-use formats, are increasingly becoming the delivery method of choice for vaccines, insulin, rheumatoid arthritis treatments, and other injectable drugs.

This report provides a comprehensive analysis of the South Korea prefilled syringes market, covering market trends, forecasts, and dynamics from 2018 to 2032. It includes detailed segmentation by design, material, closing system, application, end-user, and region. The report also examines market drivers, restraints, opportunities, and competitive landscape, offering insights into key players, their strategies, and SWOT analyses. Furthermore, it presents in-depth regional market breakdowns, historical trends, and future forecasts, supported by extensive data sources and a robust methodology. This study serves as a valuable resource for stakeholders and industry participants.

Key Market Drivers

The market’s growth is largely attributed to:
• The increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and autoimmune disorders, which require frequent parenteral administration of medications.
• A growing geriatric population in South Korea, leading to higher demand for home-based self-administration and user-friendly drug delivery systems.
• Rising emphasis on patient safety and convenience, reducing the risk of dosing errors, contamination, and needle-stick injuries compared to traditional vials and ampoules.
• The continuous expansion of South Korea’s biopharmaceutical and biotechnology industries, particularly in the development of monoclonal antibodies, vaccines, and other injectable biologics.
• Regulatory support and government investments focused on improving drug delivery safety and encouraging the adoption of innovative medical devices.

Current Market Trends

According to the newly released report, the demand for prefilled syringes is also influenced by:
• The increasing adoption of single-dose prefilled syringes, particularly for vaccines and chronic disease medications.
• The shift towards plastic prefilled syringes due to their lightweight, break-resistant properties, and enhanced patient safety.
• The rising popularity of staked needle systems, which reduce preparation steps and improve ease of administration.
• The accelerated shift towards patient-centric drug delivery post COVID-19, with prefilled syringes playing a crucial role in mass vaccination campaigns and home healthcare solutions.
• Ongoing investments in research and development (R&D) for customized and dual-chamber prefilled syringes, enabling drug reconstitution just before administration, which is highly suitable for sensitive biologics and lyophilized drugs.

Market Segmentation Insights

The South Korea prefilled syringes market is segmented by:
• Design: Single-chamber syringes dominate, but dual-chamber and customized syringes are gaining momentum due to the growing use of complex biologics.
• Material: Glass remains the preferred material due to its superior chemical resistance, although plastic alternatives are increasingly adopted for patient self-injection.
• Applications: The most prominent therapeutic areas include diabetes, anaphylaxis, rheumatoid arthritis, oncology, and emergency medicine.
• End Users: Hospitals represent the largest segment, followed by clinics and home-care settings.
• Regions: The Seoul Capital Area leads the market, owing to the concentration of healthcare institutions, pharmaceutical companies, and R&D hubs, followed by the Yeongnam, Honam, and Hoseo regions.

Opportunities and Challenges

The report identifies significant opportunities in:
• Expansion of home healthcare and self-administration trends.
• Development of advanced prefilled syringes suitable for viscous biologics and biosimilars.
• Collaborations between pharmaceutical companies and device manufacturers to produce integrated drug-device combination products.

However, the market also faces challenges, including:
• High manufacturing and compliance costs.
• Regulatory complexities linked to the MFDS (Ministry of Food and Drug Safety) and international certification requirements.
• Growing environmental concerns due to medical plastic waste from disposable syringes.

Competitive Landscape

The market features a competitive environment with participation from both global medical device leaders and domestic manufacturers. Companies are increasingly focusing on developing innovative syringe formats, expanding production capacities, and collaborating with pharmaceutical companies to meet the rising demand for prefilled syringes in both hospital and self-administration settings.

South Korea’s strong pharmaceutical and biopharmaceutical industry ecosystem, combined with increasing government initiatives and patient-centric healthcare trends, is expected to solidify its position as one of the most attractive prefilled syringe markets in the Asia-Pacific region.

This report offers actionable insights for pharmaceutical manufacturers, medical device companies, healthcare providers, investors, and policymakers seeking to understand and capitalize on the growing prefilled syringes market in South Korea.

A prefilled syringe (PFS) is a disposable syringe that is pre-loaded with a fixed dose of medication, designed for direct and convenient administration to patients. It is widely used in hospitals, clinics, and home care settings due to its ease of use, safety, and dosing accuracy. Prefilled syringes are typically made from glass or medical-grade plastic and sealed to maintain sterility. They help reduce medication errors, prevent contamination, and minimize the risk of needle-stick injuries. There are mainly two types: single-chamber and dual-chamber prefilled syringes. Single-chamber syringes are used for ready-to-inject drugs, while dual-chamber syringes are designed for drugs that require reconstitution before administration. Prefilled syringes are commonly used for vaccines, insulin, biologics, and emergency medications, supporting both hospital-based treatments and self-administration by patients.

About the Report
https://www.marketreport.jp/eng/south-korea-prefilled-syringes-market-2025/

About H&I Global Research
H&I Global Research is committed to delivering high-quality market intelligence and in-depth industry analysis to empower strategic decision-making. With a focus on identifying emerging trends and providing actionable insights, H&I Global Research supports businesses and stakeholders across a wide range of industries in navigating today’s dynamic market landscape.

• Korea Market Reports: https://www.marketreport.kr
• Korea Research Division Site: https://www.globalresearch.co.kr

PR Team
H&I Global Research Co., Ltd.
info@globalresearch.co.jp

Source:www.einpresswire.com

News Provided By

GlobeNewswire

• Mr. Kiyoshi Kaneko appointed as Chief Commercial Officer, and Ms. Mariko Nakafuji promoted to Chief Legal Officer
  

Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed as Chief Commercial Officer (CCO), and Ms. Mariko Nakafuji is promoted into the role of Chief Legal Officer (CLO).

Mr. Kaneko brings experience in business development, corporate strategy, marketing and commercial roles within the pharmaceutical and healthcare industries in Japan. At AstraZeneca, a leading global pharmaceutical company, he held the position of Senior Vice President for its commercial organization and corporate strategy in Japan, and prior to that, as Senior Vice President of its Primary Care business unit. Since 2017, he has been Representative Director and President of Luye Life Sciences Group Japan and has led strategic partnerships with Japanese life sciences companies working across pharmaceuticals, medical devices and hospital businesses. Mr. Kaneko will take up the newly created position of CCO at Nxera and will be based in Japan.

Ms. Nakafuji joined Nxera in 2021 as General Counsel and played a key role in the Company’s transformational acquisition of the Japan and South Korean businesses of Idorsia Pharmaceuticals, as well as several other strategic projects. She previously worked at Deloitte LLP and Jones Day LLP where she specialised in corporate M&A, investments and private equity with a particular focus on the life sciences sector. Ms. Nakafuji is a qualified solicitor in England and Wales. In the new role of CLO, Ms. Nakafuji will be responsible for global (ex-Japan) legal affairs and will be based in the UK.

Leadership Team (Effective 1 April 2025)

President & Chief Executive Officer – Chris Cargill
EVP, Chief Financial Officer – Hironoshin Nomura
EVP, Chief Operating Officer – Toshihiro Maeda
EVP, President of Nxera Japan, Chief Medical Officer – Makoto Sugita
EVP, President of Nxera UK, Chief Scientific Officer – Matt Barnes
EVP, Chief Accounting Officer – Kieran Johnson
EVP, Chief Compliance Officer – Kazuhiko Yoshizumi
EVP, Chief of Staff – Candelle Chong
EVP, Chief Commercial Officer – Kiyoshi Kaneko (New)
EVP, Chief Legal Officer – Mariko Nakafuji (New)

Chris Cargill, President and CEO of Nxera, commented: “I’m delighted to welcome Mr. Kaneko to our team at Nxera. His extensive experience at global pharmaceutical companies will allow us to maximize our commercial activities in Japan and will be valuable to us as we strive to become one of the leading biopharma businesses in Japan.

“It is also a great pleasure to announce the promotion of Ms. Nakafuji to the new role of Chief Legal Officer, a very well-deserved acknowledgement of her contribution to Nxera’s transformation over the past few years and her commitment to the Company’s exciting future.”

Mr. Kiyoshi Kaneko added: “Nxera is uniquely positioning itself in the Japanese pharmaceutical industry, and I’m confident that its foresight and agility will enable the company to capitalize on the major opportunities likely to arise as the industry in Japan accelerates its development. I’m very pleased to join Nxera at such an important time of change and I look forward to being part of Nxera’s ambitious growth plans through the development of its commercialization capabilities in Japan to bring new and innovative medicines to patients.”

Ms. Mariko Nakafuji, commented: “I am proud to step into the new role of Chief Legal Officer and look forward to working closely with the talented team to further advance our mission and build Nxera into a leading biopharma company in Japan and internationally.”

–END–

About Nxera Pharma
Nxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates.

Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera – Media and Investor Relations
Kentaro Tahara, VP Investor Relations and Corporate Strategy
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life

MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: www.einpresswire.com

Apple is developing a new version of its Health app that includes an AI coach that can advise users on how to get healthier, according to Bloomberg’s Mark Gurman.

Gurman first reported that something like this was in the works back in 2023, but now he says development is moving ahead, with the new features potentially coming as soon as spring or summer of 2026, with the release of iOS 19.4.

The AI coach’s advice would be based on data from across users’ medical devices, and would reportedly include food tracking. The coach is currently being trained on data from staff physicians, with Apple looking to bring in additional doctors to record health-related videos.

According to Gurman, this new service is tentatively called Health+.

Topics

Source:https://techcrunch.com/